|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.39 USD | 0.00% |
|
+0.54% | -23.56% |
| 07-20 | Collegium Pharmaceutical to Relocate HQ to One Lincoln in Boston | MT |
| 05-16 | Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director | CI |
Company Valuation: Collegium Pharmaceutical, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 650 | 778.9 | 1,004 | 924 | 1,464 | 1,148 | - | - |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | -21.57% | - | - |
| Enterprise Value (EV) | 650 | 778.9 | 1,004 | 924 | 1,464 | 1,148 | 1,148 | 1,148 |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | -21.57% | 0% | 0% |
| P/E | 10x | -31.4x | 23.9x | 15.4x | 26.8x | - | - | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0.3x | -3.83x | - | - | - |
| Capitalization / Revenue | 2.35x | 1.68x | 1.77x | 1.46x | 1.88x | 1.32x | 1.33x | 1.38x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.32x | 1.33x | 1.38x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 2.38x | 2.62x | 3.16x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 2.42x | 2.64x | 2.95x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.86 | -0.74 | 1.29 | 1.86 | 1.73 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 276.9 | 463.9 | 566.8 | 631.4 | 780.6 | 869.9 | 860.2 | 833.9 |
| EBITDA 1 | 118.3 | 266 | 367 | 401.2 | 460.5 | 482.8 | 437.7 | 362.7 |
| EBIT 1 | 17.63 | 33.32 | 167 | 169.9 | 179.6 | 473.6 | 434.2 | 389.7 |
| Net income | 71.52 | -25 | 48.16 | 69.19 | 62.87 | - | - | - |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 18.68 | 23.20 | 30.78 | 28.65 | 46.30 | 35.39 | 35.39 | 35.39 |
| Nbr of stocks (in thousands) | 34,797 | 33,572 | 32,611 | 32,250 | 31,611 | 32,434 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 22/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 1.15B | |
| 35.03x | 12.19x | 25.61x | 0.59% | 1,024B | |
| 27.48x | 6.29x | 17.54x | 2.1% | 618B | |
| 32.57x | 7.42x | 15.36x | 2.76% | 443B | |
| 19.7x | 4.68x | 11.59x | 2.83% | 349B | |
| 22.21x | 5.74x | 14.32x | 2.8% | 297B | |
| 21.76x | 4.48x | 12.7x | 1.96% | 264B | |
| 13.48x | 5.05x | 10.4x | 3.71% | 209B | |
| 25.29x | 6.61x | 11.66x | 2.62% | 208B | |
| -46.92x | 5.63x | 31.08x | 2.53% | 162B | |
| Average | 16.73x | 6.45x | 16.70x | 2.43% | 357.49B | |
| Weighted average by Cap. | 24.34x | 7.70x | 18.23x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- COLL Stock
- Valuation Collegium Pharmaceutical, Inc.
Select your edition
All financial news and data tailored to specific country editions
